Is there a clinical benefit to adaptive planning during tomotherapy in patients with head and neck cancer at risk for xerostomia?

Sei Hwan You, Song Yi Kim, Chang Geol Lee, Ki Chang Keum, Joo Ho Kim, Ik Jae Lee, Yongbae Kim, Woong Sub Koom, Jaeho Cho, Soo Kon Kim, Gwi Eon Kim

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objectives: To evaluate the necessity of adaptive planning in helical tomotherapy (TOMO) for head and neck cancer in terms of dosimetric influence on the parotid gland. Methods: Thirty-one patients underwent curative TOMO for head and neck cancer from April 2006 to April 2007. For each patient, neck diameter was monitored together with body weight at first cervical spine level through mega-voltage computed tomography during the TOMO course. Ten of 31 patients, with significant weight loss (>5%) and/or neck diameter decrease (>10%), were selected for dosimetric analysis, and parotid dose was recalculated at the fourth and last week of TOMO. Xerostomia was estimated by Radiation Therapy Oncology Group criteria. Results: The median dose was 69.96 Gy (range, 54 to 69.96 Gy) and there was no grade 3 or greater complication. Ten patients with significant neck diameter decrease and/or weight loss showed frequent grade 2 acute xerostomia (P=0.02). The volume percentage of daily fractional dose over 0.75 Gy for the parotid gland (V 0.75 Gy) increased by 23.6% at the end of TOMO. Conclusions: For patients with significant anatomic contour change; neck diameter decrease (>10%) or weight loss (>5%), adaptive planning using mega-voltage computed tomography can identify dosimetric changes and reduce deleterious side effects such as xerostomia.

Original languageEnglish
Pages (from-to)261-266
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume35
Issue number3
DOIs
Publication statusPublished - 2012 Jun 1

Fingerprint

Xerostomia
Head and Neck Neoplasms
Neck
Weight Loss
Parotid Gland
Tomography
Intensity-Modulated Radiotherapy
Radiation Oncology
Spine
Radiotherapy
Body Weight

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

You, Sei Hwan ; Kim, Song Yi ; Lee, Chang Geol ; Keum, Ki Chang ; Kim, Joo Ho ; Lee, Ik Jae ; Kim, Yongbae ; Koom, Woong Sub ; Cho, Jaeho ; Kim, Soo Kon ; Kim, Gwi Eon. / Is there a clinical benefit to adaptive planning during tomotherapy in patients with head and neck cancer at risk for xerostomia?. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2012 ; Vol. 35, No. 3. pp. 261-266.
@article{f1863e18871d4e80b597b24f0ff83447,
title = "Is there a clinical benefit to adaptive planning during tomotherapy in patients with head and neck cancer at risk for xerostomia?",
abstract = "Objectives: To evaluate the necessity of adaptive planning in helical tomotherapy (TOMO) for head and neck cancer in terms of dosimetric influence on the parotid gland. Methods: Thirty-one patients underwent curative TOMO for head and neck cancer from April 2006 to April 2007. For each patient, neck diameter was monitored together with body weight at first cervical spine level through mega-voltage computed tomography during the TOMO course. Ten of 31 patients, with significant weight loss (>5{\%}) and/or neck diameter decrease (>10{\%}), were selected for dosimetric analysis, and parotid dose was recalculated at the fourth and last week of TOMO. Xerostomia was estimated by Radiation Therapy Oncology Group criteria. Results: The median dose was 69.96 Gy (range, 54 to 69.96 Gy) and there was no grade 3 or greater complication. Ten patients with significant neck diameter decrease and/or weight loss showed frequent grade 2 acute xerostomia (P=0.02). The volume percentage of daily fractional dose over 0.75 Gy for the parotid gland (V 0.75 Gy) increased by 23.6{\%} at the end of TOMO. Conclusions: For patients with significant anatomic contour change; neck diameter decrease (>10{\%}) or weight loss (>5{\%}), adaptive planning using mega-voltage computed tomography can identify dosimetric changes and reduce deleterious side effects such as xerostomia.",
author = "You, {Sei Hwan} and Kim, {Song Yi} and Lee, {Chang Geol} and Keum, {Ki Chang} and Kim, {Joo Ho} and Lee, {Ik Jae} and Yongbae Kim and Koom, {Woong Sub} and Jaeho Cho and Kim, {Soo Kon} and Kim, {Gwi Eon}",
year = "2012",
month = "6",
day = "1",
doi = "10.1097/COC.0b013e31820dc092",
language = "English",
volume = "35",
pages = "261--266",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Is there a clinical benefit to adaptive planning during tomotherapy in patients with head and neck cancer at risk for xerostomia? / You, Sei Hwan; Kim, Song Yi; Lee, Chang Geol; Keum, Ki Chang; Kim, Joo Ho; Lee, Ik Jae; Kim, Yongbae; Koom, Woong Sub; Cho, Jaeho; Kim, Soo Kon; Kim, Gwi Eon.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 35, No. 3, 01.06.2012, p. 261-266.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Is there a clinical benefit to adaptive planning during tomotherapy in patients with head and neck cancer at risk for xerostomia?

AU - You, Sei Hwan

AU - Kim, Song Yi

AU - Lee, Chang Geol

AU - Keum, Ki Chang

AU - Kim, Joo Ho

AU - Lee, Ik Jae

AU - Kim, Yongbae

AU - Koom, Woong Sub

AU - Cho, Jaeho

AU - Kim, Soo Kon

AU - Kim, Gwi Eon

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Objectives: To evaluate the necessity of adaptive planning in helical tomotherapy (TOMO) for head and neck cancer in terms of dosimetric influence on the parotid gland. Methods: Thirty-one patients underwent curative TOMO for head and neck cancer from April 2006 to April 2007. For each patient, neck diameter was monitored together with body weight at first cervical spine level through mega-voltage computed tomography during the TOMO course. Ten of 31 patients, with significant weight loss (>5%) and/or neck diameter decrease (>10%), were selected for dosimetric analysis, and parotid dose was recalculated at the fourth and last week of TOMO. Xerostomia was estimated by Radiation Therapy Oncology Group criteria. Results: The median dose was 69.96 Gy (range, 54 to 69.96 Gy) and there was no grade 3 or greater complication. Ten patients with significant neck diameter decrease and/or weight loss showed frequent grade 2 acute xerostomia (P=0.02). The volume percentage of daily fractional dose over 0.75 Gy for the parotid gland (V 0.75 Gy) increased by 23.6% at the end of TOMO. Conclusions: For patients with significant anatomic contour change; neck diameter decrease (>10%) or weight loss (>5%), adaptive planning using mega-voltage computed tomography can identify dosimetric changes and reduce deleterious side effects such as xerostomia.

AB - Objectives: To evaluate the necessity of adaptive planning in helical tomotherapy (TOMO) for head and neck cancer in terms of dosimetric influence on the parotid gland. Methods: Thirty-one patients underwent curative TOMO for head and neck cancer from April 2006 to April 2007. For each patient, neck diameter was monitored together with body weight at first cervical spine level through mega-voltage computed tomography during the TOMO course. Ten of 31 patients, with significant weight loss (>5%) and/or neck diameter decrease (>10%), were selected for dosimetric analysis, and parotid dose was recalculated at the fourth and last week of TOMO. Xerostomia was estimated by Radiation Therapy Oncology Group criteria. Results: The median dose was 69.96 Gy (range, 54 to 69.96 Gy) and there was no grade 3 or greater complication. Ten patients with significant neck diameter decrease and/or weight loss showed frequent grade 2 acute xerostomia (P=0.02). The volume percentage of daily fractional dose over 0.75 Gy for the parotid gland (V 0.75 Gy) increased by 23.6% at the end of TOMO. Conclusions: For patients with significant anatomic contour change; neck diameter decrease (>10%) or weight loss (>5%), adaptive planning using mega-voltage computed tomography can identify dosimetric changes and reduce deleterious side effects such as xerostomia.

UR - http://www.scopus.com/inward/record.url?scp=84861528665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861528665&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e31820dc092

DO - 10.1097/COC.0b013e31820dc092

M3 - Article

C2 - 21383607

AN - SCOPUS:84861528665

VL - 35

SP - 261

EP - 266

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -